Biocompatibility
Ability of a material to perform with an appropriate host response in a specific application.
Definition
Biocompatibility evaluates how a medical device material interacts with the human body to ensure it does not produce adverse biological responses such as cytotoxicity, sensitization, or systemic toxicity. Evaluation follows ISO 10993-1, which uses a risk-based approach based on the nature and duration of body contact (surface, externally communicating, implant; limited, prolonged, long-term). Manufacturers usually start with chemical characterization under ISO 10993-18 and a toxicological risk assessment, then select biological endpoints such as cytotoxicity, sensitization, irritation and genotoxicity. FDA's guidance on ISO 10993-1 explains its expectations, and testing often needs to be done on the final, sterilized device.What this means in practice
Tests are selected per ISO 10993-1 based on contact category and duration. Material changes typically trigger re-evaluation.Examples
- A manufacturer of a new cardiovascular stent must conduct extensive biocompatibility testing, including hemocompatibility, due to its direct and prolonged contact with blood.
- Before introducing a new adhesive in the assembly of a wound dressing, a company must re-evaluate the dressing's biocompatibility, focusing on potential skin sensitization and irritation.
- An orthopedic implant manufacturer must assess the long-term biological response, including degradation product analysis, for their device due to its permanent implantation within the body.
- •Failing to consider the entire manufacturing process and all constituent materials when assessing biocompatibility is a common mistake.
- •Assuming prior biocompatibility data for a material is sufficient without considering its processing or final device application can lead to non-compliance.
- •Neglecting to re-evaluate biocompatibility after intended changes to material suppliers, manufacturing processes, or sterilization methods is a significant pitfall.
- •Not adequately addressing extractables and leachables profiles can result in incomplete biocompatibility assessments.
- •Ignoring the potential for long-term biological effects for permanently implanted devices is a serious oversight.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsManufacturing & Supply Chain
· From this learning pathFormal QMS process for evaluating, approving, and implementing changes that could affect product quality or compliance.
ISO 14644 classification of cleanrooms by airborne particulate cleanliness (ISO 1 through ISO 9).
Installation, Operational, and Performance Qualification - the three stages of equipment and process qualification.
Failure of a product, process, or system to meet specified requirements.
More in Quality & Risk
· Same categoryPeriod during which a device remains suitable for its intended use under specified conditions.
Verification step confirming a corrective or preventive action actually fixed the problem.
Process for receiving, evaluating, and responding to device complaints.
Where this term appears across MedTech Terms.
- Manufacturing & Supply ChainLesson 6 of 14
Latest in MedTech
Sources
3 sourcesEvery citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
- 1FDA Biocompatibility GuidanceTier 2 VerifiedFDAfda.gov
- 2FDA - Quality SystemsTier 2 VerifiedFDAfda.gov
- 3ISO 13485 Standard PageTier 1 VerifiedISOiso.org
Inline markers like [1] jump to the matching reference above.